HomeCompareRJN vs ABBV

RJN vs ABBV: Dividend Comparison 2026

RJN yields 49.81% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RJN wins by $287.9K in total portfolio value
10 years
RJN
RJN
● Live price
49.81%
Share price
$4.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$390.2K
Annual income
$78,847.74
Full RJN calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RJN vs ABBV

📍 RJN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRJNABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RJN + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RJN pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RJN
Annual income on $10K today (after 15% tax)
$4,234.12/yr
After 10yr DRIP, annual income (after tax)
$67,020.58/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RJN beats the other by $45,964.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RJN + ABBV for your $10,000?

RJN: 50%ABBV: 50%
100% ABBV50/50100% RJN
Portfolio after 10yr
$246.3K
Annual income
$51,809.75/yr
Blended yield
21.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RJN
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RJN buys
0
ABBV buys
0
No recent congressional trades found for RJN or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRJNABBV
Forward yield49.81%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$390.2K$102.3K
Annual income after 10y$78,847.74$24,771.77
Total dividends collected$311.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RJN vs ABBV ($10,000, DRIP)

YearRJN PortfolioRJN Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$15,681$4,981.32$11,550$430.00+$4.1KRJN
2$24,079$7,300.34$13,472$627.96+$10.6KRJN
3$36,242$10,476.63$15,906$926.08+$20.3KRJN
4$53,515$14,736.69$19,071$1,382.55+$34.4KRJN
5$77,598$20,336.96$23,302$2,095.81+$54.3KRJN
6$110,590$27,559.86$29,150$3,237.93+$81.4KRJN
7$155,039$36,707.70$37,536$5,121.41+$117.5KRJN
8$213,986$48,094.85$50,079$8,338.38+$163.9KRJN
9$291,004$62,038.39$69,753$14,065.80+$221.3KRJN
10$390,222$78,847.74$102,337$24,771.77+$287.9KRJN

RJN vs ABBV: Complete Analysis 2026

RJNStock

The index represents the value of a basket of 6 energy commodity futures contracts.

Full RJN Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RJN vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RJN vs SCHDRJN vs JEPIRJN vs ORJN vs KORJN vs MAINRJN vs JNJRJN vs MRKRJN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.